Navigation Links
TVA Medical's Minimally Invasive System for Hemodialysis Access Demonstrates Success in Clinical Study

AUSTIN, Texas, Sept. 26, 2013 /PRNewswire/ -- Preliminary data presented last week at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual scientific meeting demonstrated that TVA Medical's FLEX System can create vascular access for hemodialysis patients without traditional open surgery.  The technology is being studied outside of the United States and is currently not available in the U.S.  The Company intends to seek Food and Drug Administration clearance in the future.    


The study demonstrated that TVA Medical's vascular catheter-based FLEX System can create autogenous arterio-venous fistulas (AV fistulas) for hemodialysis patients with 94% procedural success. 

Surgical AV fistulas are the current gold-standard for hemodialysis access, but they are plagued by high failure rates and frequent revisions resulting in enormous healthcare costs.  Patients receiving surgical AV fistulas require an average of 2-3 additional interventions to achieve a usable fistula1, which can delay availability of the AV fistula for hemodialysis by 5-12 months2.  Additionally, 30-60% of AV fistulas are never usable for dialysis, despite numerous re-interventions.1,3,4

"The preliminary results of this first in human study demonstrate that we can create usable autogenous AV fistulas without open surgery," said Dheeraj K. Rajan, MD, an investigator of the FLEX-1 study and Head of Vascular and Interventional Radiology at University of Toronto, Canada. "Moving to an entirely percutaneous procedure for vascular access has the potential to dramatically improve patient care by improving fistula usability, reducing surgical wait times, and reducing complications and costs." 

"Overall, we are very pleased with the outcomes demonstrated in this clinical study," said Adrian Ebner, MD, principal investigator of the FLEX-1 study and Chief of Cardiovascular Services at the Italian Hospital, Asuncion, Paraguay.  "Many of these patients were dependent on central venous catheters, and now have a functioning permanent vascular access delivered using a minimally-invasive procedure.  I believe many patients worldwide will benefit from this procedure."

The FLEX-1 Pilot Study is a non-randomized, prospective study on the feasibility of using the FLEX System to create AV fistulas in patients with kidney failure requiring hemodialysis without open surgery.  Sixteen patients were enrolled in the initial cohort and followed for 3 months.  Additional follow-up is ongoing.

"Two million people worldwide rely on hemodialysis three times a week to sustain life, and many are subjected to multiple procedures and long duration on infection-prone catheters while they wait for a permanent workable AV fistula.  There is an unmet need for a reliable, reproducible method to connect patients to the dialysis machine in a timely manner," said Adam L. Berman, CEO of TVA Medical. "We believe our technology has the potential to benefit hemodialysis patients around the world."

About the FLEX Catheter System
The TVA Medical FLEX system uses two vascular catheters, incorporating magnets and an RF electrode, that are delivered percutaneously to an artery and vein in the arm. When the catheters are magnetically aligned and positioned under fluoroscopy, RF energy is delivered to create an arteriovenous fistula without open surgery.  No implant is left behind.

About End Stage Renal Disease and Hemodialysis
Over 2 million ESRD patients worldwide receive hemodialysis therapy and require vascular access to connect to a dialysis machine.  CMS spends $47 billion annually to treat patients with end-stage renal disease.  Vascular access is the leading cause of hospitalizations and morbidity in patients with end stage renal disease.5

About TVA Medical
TVA Medical, Inc., headquartered in Austin, Texas, is developing minimally invasive therapies for end-stage renal disease, including a catheter-based AV fistula system.  The company was founded in 2008 by serial medical device entrepreneur and cardiovascular surgeon William (Billy) E. Cohn, MD, company CEO Adam L. Berman, and Sante Ventures.  S3 Ventures led the Series B round in June 2013 that included TriStar Technology Ventures and Sante Ventures.

1 Peterson W., et al.  Clin J Am Soc Nephol.  2008 March; 3(2):437-441.
2 Lee T., et al.  Am J Kidney Dis. 2005 Sep;46(3):501-8.
3 Dember LM, et al.  JAMA. 2008 May 14;299(18):2164-71.
4 Huijbregts HJ, et al. Clin J Am Soc Nephrol. 2008 May;3(3):714-9.
5 CMS Annual Report.  End Stage Renal Disease Clinical Performance Measures Project.  2004.

SOURCE TVA Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Midwest Orthopaedics at Rush Minimally Invasive Spine Institute Opens Today
2. Endoscopy Devices Market to 2018 - Demand for Cost-Effective, Minimally Invasive Procedures and Reimbursement for New Indications to Increase Uptake
3. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
4. Peripheral Vascular Devices Market to 2018 - Increasing Demand for Minimally Invasive Endovascular Procedures Presents Growth Opportunities for Manufacturers
5. Apollo Hospitals Perform Revolutionary Minimally Invasive Knee Replacement (Resurfacement) Surgery
6. European Markets for Minimally Invasive Spinal Devices
7. Reimbursement Rates to Have Strong Effect on Adoption of Minimally Invasive Vertebral Compression Fracture Treatments
8. Studies Published in Pain Medicine Demonstrate Effectiveness of Minimally-Invasive Cooled Radiofrequency Treatment for Low Back Pain
9. Arthroscopy Devices Market to 2018 - Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Future Growth
10. Minimally Invasive Devices Raises $9 Million in Series B Financing to Commercialize Laparoscopic Visualization Product
11. MAQUET Medical Systems USA Launches The MIRA-i CS Retractor System For Use During Minimally Invasive Revascularization Procedures
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
(Date:11/30/2015)... BOSTON , November 30, 2015 ... medicines directed at up to 10 G protein-coupled receptor ... PFE ) to research and develop potential new medicines ... targets across multiple therapeutic areas. --> Heptares ... development company and wholly-owned subsidiary of Sosei Group Corporation ...
(Date:11/30/2015)... TEL AVIV, Israel , November 30, 2015 /PRNewswire/ ... EMITF ) ("Elbit" or the "Company") announced today that it ... Ministry of Food and Drug Safety (MFDS) has approved ... behavioral disorders. --> --> ... presenting a non-invasive treatment alternative that combines two technologies: ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... ... While powdered supplements and drinks can reduce food preparation time, locating the ... has found an easy to keep track of the scoop. , He developed a ... a canister or other container handy and readily accessible. As such, it prevents the ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced at the Radiology Society of North America (RSNA) annual meeting, being held ... 60% growth from 2014. Throughout 2015, the company has completed installations for ...
(Date:11/30/2015)... ... November 30, 2015 , ... Volpara Solutions ... density assessment and enterprise analytics solutions, here at the 101st Annual Radiological ... booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements of volumetric ...
(Date:11/30/2015)... ... ... It’s inevitable that everyone will experience death in his or her lifetime. Whether ... among us. It is your perspective, however, that determines how you view death in ... Sky understands that she may see death more frequently than most. As she was ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming Dec. ... care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel Corp. ...
Breaking Medicine News(10 mins):